Eli Lilly plans to file a New Drug Application with the FDA in Q4 2026
Images do not constitute a promise or representation of any particular outcome
This is not a subtle difference
The peptide carries 2-aminoisobutyric acid substitutions at positions 2 and 20 to resist dipeptidyl peptidase-4 degradation, a C-terminal amide, an N6-substituted lysine C18-diacid fatty acyl side chain for albumin binding and half-life extension, and a 2-methyl leucine substitution for selectivity tuning
Katada, S., Yanagimoto, A., Matsui, Y., Hibi, M., Osaki, N., Kobayashi, S., & Katsuragi, Y
Retatrutide works like other weight loss and type 2 diabetes medications, but what makes it different is that it can target three receptors (triple agonist) at once: Gastric inhibitory polypeptide receptor (GIP) Glucagon-like peptide-1 receptor (GLP-1) Glucagon receptors (GCG) This unique triple-action may make it more effective than GLP-1 and GLP-1/GIP medications